Dose of midazolam should be reduced during diltiazem and verapamil treatments.
about
Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem.The human CYP3A subfamily: practical considerations.Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteersA simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs.The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.Antihypertensive therapy: special focus on drug interactions.Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients.Intravenous diltiazem and CYP3A-mediated metabolism.In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolitesInhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats.Risk assessment of mechanism-based inactivation in drug-drug interactions.Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments.Adverse drug interactions in dentistry.Verapamil for cluster headache. Clinical pharmacology and possible mode of action.Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions.Application of mechanism-based CYP inhibition for predicting drug-drug interactions.Modeling and predicting drug pharmacokinetics in patients with renal impairment.Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee.Drug-drug interaction study of ACT-178882, a new renin inhibitor, and diltiazem in healthy subjects.Physiologically Based Pharmacokinetic Modeling of Palbociclib.Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics of midazolam: how long do we go?Effect of Multiple-Dose Diltiazem on the Pharmacokinetics of the Renin Inhibitor ACT-077825.A proposal for a pharmacokinetic interaction significance classification system (PISCS) based on predicted drug exposure changes and its potential application to alert classifications in product labelling.A quantitative systems pharmacology approach, incorporating a novel liver model, for predicting pharmacokinetic drug-drug interactions.Pharmacokinetic interaction between verapamil and everolimus in healthy subjects.Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric?Use of midazolam for refractory status epilepticus in pediatric patients.Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro.Intralipid prolongs survival in a rat model of verapamil toxicity.The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam.Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.Rifampin drastically reduces plasma concentrations and effects of oral midazolam.Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.
P2860
Q33891060-BB4F8953-1A3A-4F66-8083-63337699B98FQ34119161-D2933415-9CDA-43AF-911A-1561527E900CQ34347427-20A42C74-AF1C-4F1F-AD7F-DE5F50173752Q34514087-5DA0C3D9-D6A7-4C88-AA35-5FE2E74A6449Q34656231-ADA10878-3B3D-4425-A37E-6552340D9082Q35129048-201395D0-7AD4-458F-A451-680FBEC62988Q35166632-5982FB9F-591C-4668-8B52-AF009222884AQ35570981-B46AA89A-6CA1-47A0-84C9-0644DD2F75CFQ35825944-40A12F58-5775-4402-B771-B993B825F0D0Q36053886-F8E96C68-3E85-4A51-BB37-2B1B46EBFFC6Q36055276-B3C94E43-E7C7-4F54-B5C5-648AD08F3978Q36105348-A23408F4-24BC-4420-A554-4A96C1417718Q36159042-86D3D603-13C2-4528-9A4B-8ED11F9A3576Q36174265-23BACA2D-8258-4066-8A6E-E2516EEC7CDFQ36662893-A42300A9-B011-4014-8D05-3A7BA202A372Q37059176-A3070DDD-D9AF-4850-8E63-66FADCDFCC48Q37363256-C043155A-E498-4706-8679-89BC58999748Q37440022-B5BEBCE4-A327-4C63-97A3-C7EA0198AB2EQ37494640-3D833398-1B24-4A0F-92CC-F09717CF74B4Q37960638-B2565E87-A1CF-4549-8BC9-981500870B3BQ37986145-A8D4B202-593D-41C3-9912-2CA606CA2602Q39472689-279B71F3-3393-45DC-963D-F95902DB3B97Q39612151-BDF22451-378C-49FC-B1CD-BD1008FA32E5Q39796487-6A561AF3-61FD-44B1-B839-EF950C25A8B8Q39816378-62C06B37-6DA5-4E0C-BD39-31FBFE26BE5CQ39948282-25D35332-F9D3-4DC3-9A28-9A71D6F6AE91Q41072555-8CCCA115-A670-4BE0-9B6E-7564AB76094AQ42220164-9BDE64DF-DF13-45F1-9DC6-956E8CF6D2B9Q43137258-A7FD020F-E297-4715-9803-9691A0D26E2BQ43144692-BFC5E56D-0B03-42C5-8D9B-1E8BA19E949FQ45115606-DB12B808-7927-4A8B-A2C3-1E8F3C439F06Q46608474-21EA2D1C-2E23-4571-95B7-CB9E73DBC43AQ46911621-F0F871B3-D1B5-466F-8BD7-BE711F8040B9Q50867766-655332F0-337C-4F0F-81FE-D43056F24B70Q51433234-074AEBD1-501B-46E0-AA65-9400D2C5DADCQ51553057-70A916A6-EBBC-4635-A359-FDD5A3004E1CQ51577607-CAE74EB9-C530-4D4B-880B-4B94A6AC7BCDQ51584849-0AE7A607-B010-4CEE-967B-3387E2269888Q52312048-A18FC8FD-B887-4970-A87D-67A9EEBC147FQ52334679-E2CD30C0-17E6-424F-ABD3-DCF34E27639F
P2860
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@ast
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@en
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@nl
type
label
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@ast
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@en
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@nl
prefLabel
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@ast
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@en
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@nl
P2093
P2860
P1476
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
@en
P2093
Backman JT
Himberg JJ
Neuvonen PJ
Olkkola KT
P2860
P304
P356
10.1111/J.1365-2125.1994.TB04266.X
P407
P577
1994-03-01T00:00:00Z